GleamWall
中文EN

MRKR Marker Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1094038 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-30.7%
TTM net income YoY14.8%
TTM EPS YoY58.3%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-365.9%
Net margin-275.9%
FCF margin—
EBITDA margin—

Returns

ROE-77.0%
ROA-63.3%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets20.9%
Debt / equity0.00x
Current ratio4.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.55M$6.59M
R&D expense$11.80M$13.47M
SG&A expense$4.18M$4.24M
Operating income-$12.89M-$11.12M
Pretax income-$12.18M-$10.68M
Income tax-$15,156$49,953
Net income-$12.16M-$10.73M
EPS (basic)-0.79-1.19
EPS (diluted)-0.79-1.19
Weighted avg. shares (diluted)15.31M8.98M
Balance sheet
Cash & equivalents$16.07M$19.19M
Current assets$19.07M$22.02M
Total assets$19.07M$22.02M
Current liabilities$2.27M$3.46M
Total liabilities$2.27M$3.46M
Shareholders' equity$16.80M$18.56M
Shares outstanding16.70M10.70M
Cash flow statement
Operating cash flow-$12.01M-$10.91M
Financing cash flow$9.86M$14.99M
Stock-based compensation$537,540$245,864

Free plan shows the latest 2 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.